Interstitial Lung Disease With CA19-9 Elevation After Oxaliplatin and Capecitabine Adjuvant Therapy for Ileocecal Carcinoma:Report of One Case

Wenjing YANG; Guowang YANG; Ying LI; Hao WANG; Lin YANG; Weiru XU

doi:10.3881/j.issn.1000-503X.16328

PDF(1165 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (4) : 660-665. DOI: 10.3881/j.issn.1000-503X.16328

Interstitial Lung Disease With CA19-9 Elevation After Oxaliplatin and Capecitabine Adjuvant Therapy for Ileocecal Carcinoma:Report of One Case

Author information +

History +

Abstract

Both carcinoembryonic antigen and CA19-9 are considered as predictive markers of intestinal cancer recurrence and metastasis.In addition,CA19-9 elevation is considered as a predictive marker of connective tissue disease-related interstitial lung disease.The incidence of oxaliplatin and capecitabine-associated interstitial lung disease is low,and there is no report about CA19-9 as a predictive marker of oxaliplatin and capecitabine-associated interstitial lung disease.This paper reports a case of interstitial lung disease with CA19-9 elevation caused by oxaliplatin and capecitabine adjuvant therapy for ileocecal carcinoma.The change trend of serum carcinoembryonic antigen in this patient was consistent with tumor recurrence and metastasis,and that of serum CA19-9 was consistent with the severity of interstitial lung disease.Therefore,CA19-9 elevation after intestinal cancer surgery does not necessarily indicate the tumor recurrence and metastasis,and attention should be paid to the possibility of oxaliplatin and capecitabine-associated interstitial lung disease.

Key words

oxaliplatin / capecitabine / interstitial lung disease / CA19-9 / recurrence and metastasis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Wenjing YANG , Guowang YANG , Ying LI , et al . Interstitial Lung Disease With CA19-9 Elevation After Oxaliplatin and Capecitabine Adjuvant Therapy for Ileocecal Carcinoma:Report of One Case[J]. Acta Academiae Medicinae Sinicae. 2025, 47(4): 660-665 https://doi.org/10.3881/j.issn.1000-503X.16328

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Benson AB, Venook AP, Adam M, et al. Colon cancer,version 3.2024,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(2 D):e240029.DOI:10.6004/jnccn.2024.0029. Cited in this article [1]

[2]	Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2020, 31(10):1291-1305.DOI:10.1016/j.annonc.2020.06.022. Cited in this article [1]

[3]	Li C, Zhang D, Pang X, et al. Trajectories of perioperative serum tumor markers and colorectal cancer outcomes:a retrospective,multicenter longitudinal cohort study[J]. EBioMedicine, 2021,74:103706.DOI:10.1016/j.ebiom.2021.103706. Cited in this article [2]

[4]	Chu HY, Yang CY, Yeh PH, et al. Highly correlated recurrence prognosis in patients with metastatic colorectal cancer by synergistic consideration of circulating tumor cells/microemboli and tumor markers CEA/CA19-9[J]. Cells, 2021, 10(5):1149.DOI:10.3390/cells10051149. Cited in this article [1]

[5]	Ushigome M, Shimada H, Miura Y, et al. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence:serum p53 antibodies,CA19-9 and CEA[J]. Int J Clin Oncol, 2020, 25(4):622-632.DOI:10.1007/s10147-019-01597-6. Cited in this article [2]

[6]	Ushigome M, Shimada H, Kaneko T, et al. Preoperative CRP(-)/CEA(-)/CA19-9(-)/non-T4 in stage Ⅲ colorectal cancer is favorable risk for recurrence[J]. J Anus Rectum Colon, 2022, 6(4):264-273.DOI:10.23922/jarc.2022-010. Cited in this article [1]

[7]	Yu D, An G, Yao J. Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes[J]. J Clin Lab Anal, 2021, 35(9):e23944.DOI:10.1002/jcla.23944. Cited in this article [2]

[8]	Liu JM, Wang YY, Liu W, et al. Preoperative CA19-9:a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy[J]. Int J Colorectal Dis, 2021, 36(4):767-778.DOI:10.1007/s00384-020-03828-z. Cited in this article [3]

[9]	Zheng M, Lou A, Zhang H, et al. Serum KL-6,CA19-9,CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the chinese population[J]. Rheumatol Ther, 2021, 8(1):517-527.DOI:10.1007/s40744-021-00288-x. Cited in this article [2]

[10]	Wang T, Zheng XJ, Ji YL, et al. Tumour markers in rheumatoid arthritis-associated interstitial lung disease[J]. Clin Exp Rheumatol, 2016, 34(4):587-591. Cited in this article [2]

[11]	Hirose H, Higuchi T, Takagi K, et al. Association of elevated serum carbohydrate antigen 19-9 levels with extensive interstitial lung disease in patients with systemic sclerosis:a cross-sectional study[J]. Int J Rheum Dis, 2024, 27(1):e14978.DOI:10.1111/1756-185X.14978. Cited in this article [2]

[12]	Wang Q, Gao C, Zhang C, et al. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis[J]. Clin Rheumatol, 2022, 41(6):1731-1739.DOI:10.1007/s10067-022-06089-z. Cited in this article [2]

[13]	Bao Y, Zhang W, Shi D, et al. Correlation between serum tumor marker levels and connective tissue disease-related interstitial lung disease[J]. Int J Gen Med, 2021, 14:2553-2560.DOI:10.2147/IJGM.S310917. Cited in this article [2]

[14]

Balestro

, Castelli

, Bernardinello

, et al. CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis(IPF)and other interstitial lung diseases(ILDs):correlation with functional decline[J]. Chron Respir Dis, 2020,17:1479973120958428.DOI:10.1177/1479973120958428.

Cited in this article [2]

[15]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.DOI:10.3322/caac.21660. Cited in this article [1]

[16]	Lakemeyer LSS, Wittau M, Henne-Bruns D, et al. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer[J]. Diseases, 2021, 9(1):21.DOI:10.3390/diseases9010021. Cited in this article [1]

[17]	Mitsuyama Y, Shiba H, Haruki K, et al. Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis[J]. Oncol Lett, 2012, 3(4):767-771.DOI:10.3892/ol.2012.574. Cited in this article [1]

[18]	Hashizume R, Kawahara H, Ogawa M, et al. CA19-9 concentration after first-line chemotherapy is prognostic predictor of metastatic colon cancer[J]. In Vivo, 2019, 33(6):2087-2093.DOI:10.21873/invivo.11708. Cited in this article [1]

[19]	Li C, Zhang D, Pang X, et al. Trajectories of perioperative serum tumor markers and colorectal cancer outcomes:a retrospective,multicenter longitudinal cohort study[J]. EBioMedicine, 2021,74:103706.DOI:10.3892/ol.2012.574. Cited in this article [1]

[20]	Zhou W, Yang F, Peng J, et al. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage Ⅲ colon cancer after curative resection and adjuvant chemotherapy[J]. J Cancer, 2019, 10(16):3810.DOI:10.7150/jca.31375. Cited in this article [1]

[21]

Ogata

, Fujita

, Fujiyoshi

, et al. Prognostic value of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels for adjuvant chemotherapy in stage Ⅱ colorectal cancer:a nationwide multicenter retrospective study[J]. J Anus Rectum Colon, 2022, 6(4):249-258.DOI:10.23922/jarc.2022-020.

Cited in this article [1]

[22]

Jia

, Zhang

, Gou

, et al. The role of serum CEA and CA19-9 in efficacy evaluations and progression-free survival predictions for patients treated with cetuximab combined with FOLFOX4 or FOLFIRI as a first-line treatment for advanced colorectal cancer[J]. Dis Markers, 2019,2019:6812045.DOI:10.1155/2019/6812045.

Cited in this article [1]

[23]	Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer[J]. J Clin Oncol, 2003, 21(15):2904-2911.DOI:10.1200/JCO.2003.11.045. Cited in this article [1]

[24]	Shimura T, Fuse N, Yoshino T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy(FOLFOX or FOLFIRI)for colorectal cancer[J]. Ann Oncol, 2010, 21(10):2005-2010.DOI:10.1093/annonc/mdq061. Cited in this article [1]

[25]	Chan AK, Choo BA, Glaholm J. Pulmonary toxicity with oxaliplatin and capecitabine/5-fluorouracil chemotherapy:a case report and review of the literature[J]. Onkologie, 2011, 34(8-9):443-446.DOI:10.1159/000331133. Cited in this article [1]

[26]	Zhou LY, Chen MH, Shi JN, et al. Severe interstitial pneumonia caused by cetuximab:a case report and review of the literature[J]. Anticancer Drugs, 2021, 32(10):1123-1126.DOI:10.1097/CAD.0000000000001104. Cited in this article [1]

[27]	Wan Z, Yang R. Severe interstitial pneumonia possibly induced by capecitabine[J]. Minerva Med, 2023, 114(4):556-558.DOI:10.23736/S0026-4806.23.08613-5. Cited in this article [1]

[28]	De Weerdt A, Dendooven A, Snoeckx A, et al. Prognosis and treatment of FOLFOX therapy related interstitial pneumonia:a plea for multimodal immune modulating therapy in the respiratory insufficient patient[J]. BMC Cancer, 2017, 17(1):586.DOI:10.1186/s12885-017-3576-y. Cited in this article [1]

[29]	Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies:expert opinion on diagnosis and treatment[J]. ESMO Open, 2022, 7(2):100404.DOI:10.1016/j.esmoop.2022.100404. Cited in this article [1]

[30]	Moskovitz M, Wollner M, Haim N. Oxaliplatin-induced pulmonary toxicity in gastrointestinal malignancies:two case reports and review of the literature[J]. Case Rep Oncol Med, 2015,2015:341064.DOI:10.1155/2015/341064. Cited in this article [1]

[31]	陈佳音, 马洁, 童刚领, 等. 奥沙利铂相关性肺损伤的文献分析[J]. 中国医院药学杂志, 2021, 41(10):1059-1063.DOI:10.13286/j.1001-5213.2021.10.14. Cited in this article [1]